{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:01:24Z","timestamp":1768284084617,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1053\/j.ajkd.2005.06.020","type":"journal-article","created":{"date-parts":[[2005,12,13]],"date-time":"2005-12-13T09:09:51Z","timestamp":1134464991000},"page":"713-719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Rosiglitazone Reduces Insulin Requirement and C-Reactive Protein Levels in Type 2 Diabetic Patients Receiving Peritoneal Dialysis"],"prefix":"10.1053","volume":"46","author":[{"given":"Teresa Yuk-Hwa","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheuk-Chun","family":"Szeto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Ming","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Bong","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher Wai-Kei","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip Kam-Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2005.06.020_bib1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/diabetes.47.4.507","article-title":"PPAR","volume":"47","author":"Spiegelman","year":"1998","journal-title":"Diabetes"},{"key":"10.1053\/j.ajkd.2005.06.020_bib2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/j.1875-9114.1998.tb03928.x","article-title":"The role of troglitazone in treating the insulin resistance syndrome","volume":"18","author":"Cranberry","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.ajkd.2005.06.020_bib3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.7326\/0003-4819-128-3-199802010-00002","article-title":"Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, doubled-blind, placebo-controlled trial","volume":"128","author":"Maggs","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2005.06.020_bib4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJM199803263381302","article-title":"Effect of troglitazone in insulin treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group","volume":"338","author":"Schwartz","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2005.06.020_bib5","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.2337\/diacare.24.7.1226","article-title":"Rosiglitazone Clinical Trials Study Group","volume":"24","author":"Raskin","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ajkd.2005.06.020_bib6","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2337\/diabetes.50.5.1021","article-title":"Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death","volume":"50","author":"Finegood","year":"2001","journal-title":"Diabetes"},{"key":"10.1053\/j.ajkd.2005.06.020_bib7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2125.1999.00030.x","article-title":"Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone","volume":"48","author":"Baldwin","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/j.ajkd.2005.06.020_bib8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2337\/diacare.24.1.168","article-title":"Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis","volume":"24","author":"Lenhard","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ajkd.2005.06.020_bib9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s001250050045","article-title":"Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes","volume":"43","author":"Raskin","year":"2000","journal-title":"Diabetologia"},{"key":"10.1053\/j.ajkd.2005.06.020_bib10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/147323000203000405","article-title":"Pharmacokinetics of rosiglitazone in patients with end-stage renal disease","volume":"30","author":"Thompson-Culkin","year":"2002","journal-title":"J Int Med Res"},{"key":"10.1053\/j.ajkd.2005.06.020_bib11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1742-1241.2000.tb11914.x","article-title":"Rosiglitazone","volume":"54","author":"Goldstein","year":"2000","journal-title":"Int J Clin Pract"},{"key":"10.1053\/j.ajkd.2005.06.020_bib12","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/01.ATV.21.3.372","article-title":"Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice","volume":"21","author":"Chen","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.ajkd.2005.06.020_bib13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2337\/diacare.24.2.392","article-title":"Control of vascular cell proliferation and migration by PPAR-gamma","volume":"24","author":"Hsueh","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ajkd.2005.06.020_bib14","series-title":"Handbook of Dialysis","first-page":"383","article-title":"Nutrition","author":"Blumenkrantz","year":"1994"},{"key":"10.1053\/j.ajkd.2005.06.020_bib15","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1681\/ASN.V62198","article-title":"Symptomatic fluid retention in patients on continuous peritoneal dialysis","volume":"6","author":"Tzamaloukas","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2005.06.020_bib16","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/ndt\/12.10.2105","article-title":"Poor pre-dialysis glycemic control is a predictor of mortality in type II diabetic patients on maintenance hemodialysis","volume":"12","author":"Wu","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2005.06.020_bib17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2005.06.020_bib18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/039139889902201001","article-title":"Recommendations for glucose control in diabetics on CAPD","volume":"22","author":"Passadakis","year":"1999","journal-title":"Int J Artif Organs"},{"key":"10.1053\/j.ajkd.2005.06.020_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/ki.1982.132","article-title":"Insulin resistance in uremia mediated by post binding defects","volume":"22","author":"Smith","year":"1982","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2005.06.020_bib20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0272-6386(99)70080-6","article-title":"Clinical and biochemical characteristics of type 2 diabetic patients with end stage renal failure on continuous ambulatory peritoneal dialysis\u2014Relationships with insulin requirement","volume":"34","author":"Wong","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2005.06.020_bib21","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/01.HYP.15.6.861","article-title":"Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II","volume":"15","author":"Rocchini","year":"1990","journal-title":"Hypertension"},{"key":"10.1053\/j.ajkd.2005.06.020_bib22","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2337\/diab.46.6.1025","article-title":"Acute postchallenge hyperinsulinemia predicts weight gain","volume":"46","author":"Sigal","year":"1997","journal-title":"Diabetes"},{"issue":"suppl 5","key":"10.1053\/j.ajkd.2005.06.020_bib23","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal failure","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2005.06.020_bib24","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2005.06.020_bib25","first-page":"82","article-title":"Tumor necrosis factor alpha as a uremic toxin","volume":"15","author":"Espinoza","year":"1999","journal-title":"Adv Perit Dial"},{"key":"10.1053\/j.ajkd.2005.06.020_bib26","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1159\/000065018","article-title":"C-Reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure","volume":"91","author":"Panichi","year":"2002","journal-title":"Nephron"},{"key":"10.1053\/j.ajkd.2005.06.020_bib27","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1046\/j.1523-1755.1999.00422.x","article-title":"Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure","volume":"55","author":"Stenvinkel","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2005.06.020_bib28","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1194\/jlr.M300077-JLR200","article-title":"PPAR(alpha) and PPAR(gamma) activators suppress the monocyte-macrophage poB-48 receptor","volume":"44","author":"Haraguchi","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1053\/j.ajkd.2005.06.020_bib29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/01.CIR.101.3.235","article-title":"Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators","volume":"101","author":"Pasceri","year":"2000","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2005.06.020_bib30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/34184","article-title":"PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines","volume":"291","author":"Jiang","year":"1998","journal-title":"Nature"},{"key":"10.1053\/j.ajkd.2005.06.020_bib31","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1161\/hc4601.099403","article-title":"In vivo myocardial protection from ischemia\/reperfusion injury by the PPAR agonist rosiglitazone","volume":"104","author":"Yue","year":"2001","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2005.06.020_bib32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/34178","article-title":"The PPAR is a negative regulator of macrophage activation","volume":"391","author":"Ricote","year":"1998","journal-title":"Nature"},{"key":"10.1053\/j.ajkd.2005.06.020_bib33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/01.CIR.0000025403.20953.23","article-title":"Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus","volume":"106","author":"Haffner","year":"2002","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2005.06.020_bib34","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/0091270002250602","article-title":"Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency","volume":"43","author":"Chapelsky","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.ajkd.2005.06.020_bib35","first-page":"CR175","article-title":"Role of fasting serum C-peptide as a predictor of cardiovascular risk associated with the metabolic X-syndrome","volume":"8","author":"Haban","year":"2002","journal-title":"Med Sci Monit"},{"key":"10.1053\/j.ajkd.2005.06.020_bib36","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1161\/01.CIR.0000103683.99399.7E","article-title":"Thiazolidinedione use, fluid retention and congestive heart failure. A consensus statement from the AHA and ADA","volume":"108","author":"Nesto","year":"2003","journal-title":"Circulation"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638605009170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638605009170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:30:46Z","timestamp":1759455046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638605009170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0272638605009170"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2005.06.020","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rosiglitazone Reduces Insulin Requirement and C-Reactive Protein Levels in Type 2 Diabetic Patients Receiving Peritoneal Dialysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2005.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}